ALGS — Aligos Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1799448 ·
Last close
$5.51
Market Cap
$30.00M
52W High
$13.69
52W Low
$3.98
ADV30
57,313
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 27,778,000 | — | -1,890,000 | -1,504,000 | 66,327,000 | 30,381,000 | 34,443,000 |
| Mar 2026 | 2,830,000 | — | -26,929,000 | -23,040,000 | 64,558,000 | 29,980,000 | 32,769,000 |
| Dec 2025 | 169,000 | — | -21,814,000 | -19,881,000 | 88,533,000 | 18,303,000 | 34,988,000 |
| Sep 2025 | 741,000 | — | -28,361,000 | -31,537,000 | 109,764,000 | 41,946,000 | 37,931,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-94,168,000
Investing CF
$105,592,000
Financing CF
$228,000
CapEx
$-355,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-7.30
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-666,745,000
Inventory
—
Receivables
$27,778,000
ST Investments
$0
EBIT TTM
$-78,994,000
Pretax Income TTM
$-72,748,000
Interest Exp TTM
—
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$31,518,000
EBITDA
$-77,916,000
Free Cash Flow
$-61,390,248
Enterprise Value
$5,719,593
Total Cash
$30,381,000
Total Debt
$3,504,000
Shares Out
5,444,558
Trailing EPS
$-7.71
Book Value
$5.11
ROE
-113.6%
ROA
-49.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,186,000 | -87,985,000 | -24,193,000 | 88,533,000 | 34,988,000 | 53,545,000 | -82,503,000 |
| Dec 2024 | 3,945,000 | -89,154,000 | -131,211,000 | 70,094,000 | 99,067,000 | -28,973,000 | -80,743,000 |
| Dec 2023 | 15,529,000 | -88,127,000 | -87,679,000 | 151,527,000 | 59,447,000 | 92,080,000 | -78,997,000 |
| Dec 2022 | 13,907,000 | -97,580,000 | -96,046,000 | 146,693,000 | 42,793,000 | 103,900,000 | -79,389,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-5.25
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ATYR | aTYR PHARMA INC | $29.92M | $0.31 | — |
| EVAX | Evaxion A/S | $30.13M | $3.34 | — |
| LONA | LeonaBio, Inc. | $30.62M | $3.25 | — |
| CVM | CEL SCI CORP | $29.37M | $1.67 | — |
| QNCX | Quince Therapeutics, Inc. | $31.53M | $31.00 | — |
News headlines (Yahoo Finance, 1h cache)
Aligos Therapeutics Shares Rise 7.6% Premarket Following Recent Company Updates
2026-09-02 10:45 · Yahoo
Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China
2026-08-12 20:05 · Yahoo
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results
2026-08-06 12:00 · Yahoo
Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026
2026-07-30 12:00 · Yahoo
Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection
2026-07-13 12:00 · Yahoo
Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026
2026-05-13 06:05 · Yahoo
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
2026-05-07 20:05 · Yahoo
Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026
2026-04-30 20:05 · Yahoo
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-04-24 12:00 · Yahoo
Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
2026-04-16 10:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.